Advice
Following a resubmission
Eflornithine 11.5% cream (Vaniqa) is accepted for restricted use within NHS Scotland for the treatment of facial hirsutism in women. It is restricted to use in women for whom alternative drug therapy is ineffective, contraindicated or considered inappropriate. Eflornithine 11.5% cream, as a topical treatment, may offer advantages over existing Therapy for some women as it avoids the risks associated with systemic therapies.
Download detailed advice43KB (PDF)
Medicine details
- Medicine name:
- Eflornithine 11.5% cream (Vaniqa®)
- SMC ID:
- 159/05
- Indication:
- Facial hirsutism in woman
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Skin
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 12 September 2005